(688105)"NANJING VAZYME BIOTECH CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688105 · · 17 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information presented, with no significant omissions or misleading statements. It highlights significant changes in revenue and net profit compared to the previous year, indicating a positive trend in financial performance. The report also discusses the company's ongoing share buyback plan and recent changes in major shareholder stakes.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Nanjing Vazyme Biotech Co., Ltd. on 6ix
Earlier from Nanjing Vazyme Biotech
- (688105)"NANJING VAZYME BIOTECH CO., LTD."Indicative Announcement on Change in Equity Interests of the Controlling Shareholder Reaching Integral Multiples of 1% and 5% and Disclosure of Simplified Report on Changes in Equity Interests
- (688105)"NANJING VAZYME BIOTECH CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Completion of Shareholding Reduction Plan by Shareholder Holding More Than 5% of the Shares and Results of Shareholding Reduction
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry
Follow Nanjing Vazyme Biotech into a list and get an email when it puts out news.
Follow Nanjing Vazyme Biotech